#Alexion Pharma acquires #Enobia Pharma

In Uncategorized by Ana Lloyd

Alexion, Enobia, Julie Anne Smith, World Orphan Drug Congress, Hypophosphatasia Alexion Pharmaceuticals acquired privately held Enobia Pharma Corp. expanding its presence in the orphan drug scientific market and first potential treatment for patients with Hypophosphatasia.

Much of Alexion’s efforts have focused on educating physicians about such rare disorders, which can take years to be properly diagnosed, as opposed to focusing on the drug. Enobia focuses on development of therapies to treat patients with serious genetic metabolic bone disorders.

Julie Anne Smith, Enobia’s Chief Commercial Officer will be at the World Orphan Drug Congress USA 2012, North America’s leading orphan drug conference that  brings together leading pharma and biotech executives to strategize about the opportunities and challenges in commercializing treatments for rare and ultra-rare diseases.

Check the agenda or receive more information downloading the brochure.